PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 56 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 1,821 | +0.8% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 1,807 | +1.2% | 0.00% | – |
| Q1 2022 | $2,000 | -60.0% | 1,786 | +0.1% | 0.00% | – |
| Q4 2021 | $5,000 | -84.8% | 1,785 | -83.2% | 0.00% | – |
| Q3 2021 | $33,000 | +371.4% | 10,597 | +487.4% | 0.00% | – |
| Q2 2021 | $7,000 | -66.7% | 1,804 | -71.4% | 0.00% | – |
| Q1 2021 | $21,000 | -74.7% | 6,317 | -74.5% | 0.00% | – |
| Q4 2020 | $83,000 | +12.2% | 24,792 | +17.8% | 0.00% | – |
| Q3 2020 | $74,000 | -35.1% | 21,045 | -15.8% | 0.00% | – |
| Q2 2020 | $114,000 | +107.3% | 24,982 | +48.4% | 0.00% | – |
| Q1 2020 | $55,000 | +10.0% | 16,832 | +107.0% | 0.00% | – |
| Q4 2019 | $50,000 | -45.7% | 8,133 | -63.1% | 0.00% | – |
| Q3 2019 | $92,000 | -56.4% | 22,014 | +37.2% | 0.00% | – |
| Q2 2019 | $211,000 | – | 16,046 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |